Xenon Pharmaceuticals (XENE) Accumulated Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Accumulated Expenses data on file, last reported at $32.5 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $32.5 million, up 220.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.5 million (up 220.51% YoY), and the FY2025 annual result was $36.4 million, up 201.59% from the prior year.
• Accumulated Expenses declined to $32.5 million in Q1 2026 per XENE's latest filing, from $36.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $36.4 million in Q4 2025 and troughed at $2.1 million in Q1 2022.
• A 5-year average of $10.2 million and a median of $6.2 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses fell 1.97% in 2022, then jumped 220.51% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $5.8 million in 2022, then rose by 27.51% to $7.4 million in 2023, then jumped by 62.44% to $12.1 million in 2024, then soared by 201.59% to $36.4 million in 2025, then retreated by 10.64% to $32.5 million in 2026.
• Business Quant data shows XENE's Accumulated Expenses at $32.5 million in Q1 2026, $36.4 million in Q4 2025, and $11.1 million in Q3 2025.